French drugmaker Adocia, encouraged by the outcome of its project BC Lispro, has set its goal on partnering up with companies that have “more mature projects”, such is Eli Lilly with whom Adocia worked on BC Lispro.
The company focused on diabetes treatment said on Thursday that it will change its business model and use its technology on more advanced stage.
“We want to create more long-term value for the company and its shareholders.” said Gérard Soula, Chairman and CEO.
BC Lispro has had 6 positive clinical studies that were done with with Eli Lilly.
Adocia has two more studies planned in 2017, to prepare BC Lispro for Phase 3. Eli Lilly’s decision is expected in 2017.
The French drugmaker plans to study of human glucagon, one of the two prandial insulin lispro combinations and one of the two basal insulin glargine combinations.
It has other projects combining lispro prandial insulin with pramlintide, and also insulin lispro with a GLP-1 receptor agonist, exenatide, which could help glycemic control and weight loss for type 1 diabetes people.
“These various programs make Adocia’s portfolio of projects one of the most differentiated in the industry with a particular focus on improving treatment for people with type 1 diabetes,” the company says.
For people with type 2 diabetes, Adocia has prepared combinations of insulin glargine with two GLP-1 RAs, dulaglutide (Trulicity, Eli Lilly) and liraglutide (Victoza, Novo Nordisk) using BioChaperone technology.
Adocia expressed belief that, with about €58 million of cash at December 31, 2016, it has enough to support the development of its products. But for the new strategy to take effect, Adocia plans a private placement to increase its capital.